AVR vs NVCR vs TMCI vs ATRC vs EW

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -1. 2% for Anteris Technologies Global Corp. (AVR). Edwards Lifesciences Corporation (EW) offers the better valuation at 43. 7x trailing P/E (26. 6x forward), making it the more compelling value choice. Analysts rate Anteris Technologies Global Corp. (AVR) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Edwards Lifesciences Corporation is actually cheaper at 26.

6x.

Over the past 5 years, Anteris Technologies Global Corp.

(AVR) delivered a total return of +17. 5%, compared to -93. 9% for Treace Medical Concepts, Inc. (TMCI). Over 10 years, the gap is even starker: EW returned +125. 5% versus TMCI's -92. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.

64β versus Treace Medical Concepts, Inc. 's 2. 19β — meaning TMCI is approximately 245% more volatile than EW relative to the S&P 500. On balance sheet safety, Anteris Technologies Global Corp. (AVR) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus -1. 2% for Anteris Technologies Global Corp. (AVR). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -194. 5% for Anteris Technologies Global Corp.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus -28. 2% for Anteris Technologies Global Corp. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -29. 0% for AVR. At the gross margin level — before operating expenses — TMCI leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Edwards Lifesciences Corporation (EW) trades at 26.

6x forward P/E versus 428. 7x for AtriCure, Inc. — 402. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVR: 128. 0% to $15. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Edwards Lifesciences Corporation (EW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

64), +125. 5% 10Y return). Treace Medical Concepts, Inc. (TMCI) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EW: +125. 5%, TMCI: -92. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.